Equities analysts expect that DexCom, Inc. (NASDAQ:DXCM) will post $612.17 million in sales for the current quarter, according to Zacks. Eight analysts have made estimates for DexCom’s earnings, with the lowest sales estimate coming in at $603.10 million and the highest estimate coming in at $618.10 million. DexCom posted sales of $500.90 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 22.2%. The company is scheduled to announce its next quarterly earnings report on Tuesday, October 26th.
According to Zacks, analysts expect that DexCom will report full-year sales of $2.39 billion for the current year, with estimates ranging from $2.36 billion to $2.40 billion. For the next year, analysts anticipate that the firm will post sales of $2.91 billion, with estimates ranging from $2.80 billion to $3.07 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover DexCom.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 29th. The medical device company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.33. The company had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $548.02 million. DexCom had a net margin of 24.45% and a return on equity of 16.17%.
Shares of DXCM stock traded down $17.18 during trading on Friday, hitting $543.56. The company had a trading volume of 10,458 shares, compared to its average volume of 760,155. The company has a quick ratio of 5.25, a current ratio of 5.78 and a debt-to-equity ratio of 0.86. The stock’s 50-day moving average is $515.81 and its two-hundred day moving average is $431.91. The stock has a market capitalization of $52.59 billion, a price-to-earnings ratio of 106.81, a price-to-earnings-growth ratio of 14.59 and a beta of 0.77. DexCom has a 52 week low of $305.63 and a 52 week high of $579.00.
In related news, SVP Sumi Shrishrimal sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 16th. The stock was sold at an average price of $450.00, for a total value of $180,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Andrew K. Balo sold 2,974 shares of DexCom stock in a transaction that occurred on Tuesday, July 6th. The stock was sold at an average price of $430.14, for a total value of $1,279,236.36. Following the completion of the sale, the insider now directly owns 16,533 shares in the company, valued at approximately $7,111,504.62. The disclosure for this sale can be found here. Insiders sold 46,240 shares of company stock worth $23,891,179 over the last three months. Insiders own 0.52% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Janus Henderson Group PLC increased its position in shares of DexCom by 201.4% during the 1st quarter. Janus Henderson Group PLC now owns 1,868,977 shares of the medical device company’s stock valued at $671,700,000 after purchasing an additional 1,248,830 shares during the last quarter. Sands Capital Management LLC grew its position in DexCom by 28.2% in the 1st quarter. Sands Capital Management LLC now owns 2,936,502 shares of the medical device company’s stock valued at $1,055,349,000 after acquiring an additional 645,568 shares during the last quarter. Nuveen Asset Management LLC grew its position in DexCom by 42.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,830,424 shares of the medical device company’s stock valued at $781,591,000 after acquiring an additional 542,070 shares during the last quarter. Artisan Partners Limited Partnership grew its position in DexCom by 29.8% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,967,829 shares of the medical device company’s stock valued at $707,218,000 after acquiring an additional 451,362 shares during the last quarter. Finally, Clearbridge Investments LLC bought a new position in DexCom in the 2nd quarter valued at $141,443,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
Featured Story: What are the disadvantages of after-hours trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.